Highlights from the 42nd annual meeting of the American Society of Clinical Oncology Atlanta, GA, USA, 2-6 June 2006.
The results of approximately 3700 preclinical and clinical studies were presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) held 2-6 June 2006, in Atlanta, Georgia. The annual ASCO meeting is the largest forum in which oncology professionals from around the world report the latest advances in cancer research, encompassing a wide spectrum of subjects on molecular biology, prevention, diagnosis and therapy of tumours. The present report summarises some of the more important results of the studies presented at the meeting. In particular, the authors focused on findings from randomised Phase III trials that, in their opinion, are most likely to have an immediate effect on clinical practice. The top advances were grouped into four major themes (breast cancer, colorectal cancer, non-small cell lung cancer and selected presentations from the plenary session). In addition, selected Phase I and II studies on promising novel therapeutic agents were briefly described. Finally, a 'question and answer' format was adopted to report results of interesting studies on some hot topics.
Puglisi
Fabio
F
Azienda Ospedaliero-Universitaria di Udine, Dipartimento di Oncologia, Piazzale S.M. Misericordia 15, I-33100, Udine, Italy. fabio.puglisi@med.uniud.it
Andreetta
Claudia
C
Fasola
Gianpiero
G
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D012955:Societies, Medical; D014481:United States